


Baxject II/Baxject II Hi-Flow® Reconstitution Devices
Background information: Since the development of intravenous therapies, the presence of particulate matter in injectable drugs has been a concern for clinicians and patients. While some particles can come from outside sources (e.g. when the...

EHC January 2023 Newsletter

EHC Think Tank 2022 Activity Report

EHC publishes New Produce Report 2022 Vol. 2

EHC November 2022 Newsletter

BioMarin announced an additional serious adverse event in its gene therapy clinical trial for haemophilia A

BioMarin reports a serious adverse event for its phase I/II gene therapy trial for haemophilia A
February 4, 2022 – BioMarin’s gene therapy (valoctocogene roxaparvovec) for haemophilia A is currently in development and not yet licensed by regulators. BioMarin has completed dosing 134 patients in its phase 3 clinical study...
